Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin

Journal Article · Fri Apr 01 04:00:00 EST 1988 · Clin. Nucl. Med.; (United States)

DOI:https://doi.org/10.1097/00003072-198804000-00007· OSTI ID:7138639

Keeling, C A; Basso, L V

A 47-year-old man with multiple endocrine neoplasia (MEN) type 2a syndrome in whom metaiodobenzylguanidine (MIBG) concentrated in lesions from metastatic medullary carcinoma of the thyroid is reported. A somatostatin analogue (Sandostatin SMS 201-995) alleviated the symptoms of flushing and diarrhea associated with the elevated calcitonin levels but it did not alter either the course of the disease or the MIBG images. A review of the literature is presented of the noncatecholamine secreting tumors associated with MIBG uptake. Similarities between this case and metastatic carcinoid syndrome are discussed. 27 references.

• Research Organization: Stanford Univ. School of Medicine, CA (USA)
• OSTI ID: 7138639
• Journal Information: Clin. Nucl. Med.; (United States), Journal Name: Clin. Nucl. Med.; (United States) Vol. 13:4; ISSN CNMED
• Country of Publication: United States
• Language: English

Related Subjects

560161* -- Radionuclide Effects
Kinetics
& Toxicology-- Man
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANTINEOPLASTIC DRUGS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
CARCINOMAS
DAYS LIVING RADIOISOTOPES
DISEASES
DOCUMENT TYPES
DRUGS
ENDOCRINE GLANDS
GLANDS
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
NEOPLASMS
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PATIENTS
RADIOISOTOPES
RADIONUCLIDE KINETICS
REVIEWS
SOMATOSTATIN
THYROID
UPTAKE